Bellingham, Washington – In the realm of biomedical sciences, the quest for accurate and efficient diagnostic tools is ever-evolving. One such promising innovation making waves is the photoacoustic (PA) technique. In the past decade, PA imaging has emerged as a viable imaging modality demonstrated in many clinical applications with promising...
Latest News
SEOUL, South Korea and HYDERABAD, India — The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, today announced that it has commenced a technology transfer of simplified Oral Cholera Vaccine (OCV-S) to Biological E. Limited...
BAR HARBOR, Maine – The Jackson Laboratory, an independent, nonprofit biomedical research institution, announced the appointment of Lon Cardon, Ph.D., FMedSci, a pioneer in human genetics and drug discovery, as its next president and chief executive officer. Effective on November 29, Cardon will succeed current President and CEO Edison Liu...
Changwon, South Korea – Dr. Min-young Lee and Dr. Sung-gyu Park of the Advanced Bio and Healthcare Materials Research Division at KIMS have developed a technology that can detect cancer mutant genes in blood with the world’s highest sensitivity of 0.000000001% based on plasmonic nanomaterials for optical signal amplification. The...
Reported cases of multi-system inflammatory syndrome (MIS-C) in children and adolescents who had received at least one COVID-19 vaccine dose were rare (estimated at one case per million vaccinated individuals in this age group). The reporting rate for cases without evidence of SARS-CoV-2 infection was 0.3 cases per million vaccinated...
PHILADELPHIA – Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced today that the data from the Phase 3 PROPEL pivotal trial, assessing the efficacy, safety and tolerability of AT-GAA in adults with late-onset Pompe disease compared to the standard of...
Relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection Addition of relacorilant did not increase side-effects, compared to nab-paclitaxel monotherapy Results presented in late-breaking podium presentation at ASCO 2025 with simultaneous publication in The Lancet REDWOOD CITY, Calif. — Corcept...
Marks the First-Ever Global Pediatric Trial for Menin Inhibitors The PedAL (Pediatric Acute Leukemia) Master Trial is at the heart of LLS’s Dare to Dream Project to transform treatment and care for kids with blood cancer WASHINGTON, DC — The Leukemia & Lymphoma Society (LLS) announced today the first...
WASHINGTON — George Dahlman, senior vice president of public policy for The Leukemia & Lymphoma Society (LLS), testified today before the U.S. Senate Subcommittee on Defense Appropriations, calling for funding for a dedicated, stand-alone blood cancer research program at the Department of Defense (DoD). The Institute of Medicine (IOM) has...
PRINCETON, N.J. – The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Sentinel Oncology (Sentinel), a drug discovery company. The McQuade Center for Strategic Research and Development at Otsuka in...